Atea Pharmaceuticals, Inc. Operating Cash Flow
Atea Pharmaceuticals, Inc. (AVIR) reported Operating Cash Flow of -$83.47 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Atea Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$37.08M.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$46.39M.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$28.22M.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$40.38M.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$132.03M.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$135.50M.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$85.39M.
- Atea Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$120.98M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$37.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$83.47M 10-Q · filed 2026-08-12 | -$111.70M derived: sum of 3 quarters · filed 2026-08-12 | -$152.07M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$46.39M 10-Q · filed 2026-05-12 | -$74.61M derived: sum of 2 quarters · filed 2026-05-12 | -$114.99M derived: sum of 3 quarters · filed 2026-05-12 | -$147.86M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$28.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$68.60M derived: sum of 2 quarters · filed 2026-03-05 | -$101.47M derived: sum of 3 quarters · filed 2026-08-12 | -$132.03M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$40.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$73.25M derived: sum of 2 quarters · filed 2026-08-12 | -$103.81M 10-Q · filed 2025-11-12 | -$134.21M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$32.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$63.43M 10-Q · filed 2026-08-12 | -$93.83M derived: sum of 3 quarters · filed 2026-08-12 | -$116.86M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$30.56M 10-Q · filed 2026-05-12 | -$60.96M derived: sum of 2 quarters · filed 2026-05-12 | -$84.00M derived: sum of 3 quarters · filed 2026-05-12 | -$126.20M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$30.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$53.43M derived: sum of 2 quarters · filed 2026-03-05 | -$95.63M derived: sum of 3 quarters · filed 2026-03-05 | -$135.50M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$23.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$65.24M derived: sum of 2 quarters · filed 2025-11-12 | -$105.10M 10-Q · filed 2025-11-12 | -$126.94M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$42.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$82.07M 10-Q · filed 2025-08-07 | -$103.90M derived: sum of 3 quarters · filed 2025-08-07 | -$121.49M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$39.87M 10-Q · filed 2025-05-12 | -$61.70M derived: sum of 2 quarters · filed 2025-05-12 | -$79.29M derived: sum of 3 quarters · filed 2025-05-12 | -$95.41M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$21.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$39.42M derived: sum of 2 quarters · filed 2025-03-06 | -$55.55M derived: sum of 3 quarters · filed 2025-03-06 | -$85.39M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$17.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$33.71M derived: sum of 2 quarters · filed 2024-11-07 | -$63.56M 10-Q · filed 2024-11-07 | -$85.11M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$16.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$45.97M 10-Q · filed 2024-08-07 | -$67.52M derived: sum of 3 quarters · filed 2024-08-07 | -$88.76M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$29.85M 10-Q · filed 2024-05-14 | -$51.40M derived: sum of 2 quarters · filed 2024-05-14 | -$72.64M derived: sum of 3 quarters · filed 2024-05-14 | -$91.82M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$21.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$42.79M derived: sum of 2 quarters · filed 2024-02-28 | -$61.97M derived: sum of 3 quarters · filed 2024-02-28 | -$120.98M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$21.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$40.43M derived: sum of 2 quarters · filed 2023-11-08 | -$99.44M 10-Q · filed 2023-11-08 | -$174.86M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$19.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$78.19M 10-Q · filed 2023-08-08 | -$153.62M derived: sum of 3 quarters · filed 2023-08-08 | -$131.01M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$59.01M 10-Q · filed 2023-05-08 | -$134.43M derived: sum of 2 quarters · filed 2023-05-08 | -$111.83M derived: sum of 3 quarters · filed 2023-05-08 | -$129.18M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$75.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$52.82M derived: sum of 2 quarters · filed 2023-02-28 | -$70.17M derived: sum of 3 quarters · filed 2023-02-28 | -$87.00M 10-K · filed 2023-02-28 |
| 2021-09-30 | $22.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $5.25M derived: sum of 2 quarters · filed 2022-11-07 | -$11.58M 10-Q · filed 2022-11-07 | $306.94M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$17.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$34.19M 10-Q · filed 2022-08-08 | $284.34M derived: sum of 3 quarters · filed 2023-02-28 | $274.86M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$16.84M 10-Q · filed 2022-05-10 | $301.68M derived: sum of 2 quarters · filed 2023-02-28 | $292.20M derived: sum of 3 quarters · filed 2023-02-28 | $284.40M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $318.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $309.04M derived: sum of 2 quarters · filed 2023-02-28 | $301.24M derived: sum of 3 quarters · filed 2023-02-28 | $296.73M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$9.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$17.28M derived: sum of 2 quarters · filed 2021-11-12 | -$21.79M 10-Q · filed 2021-11-12 | -$25.73M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$7.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$12.31M 10-Q · filed 2021-08-12 | -$16.25M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2020-03-31 | -$4.51M 10-Q · filed 2021-05-13 | -$8.45M derived: sum of 2 quarters · filed 2022-02-28 | ||
| 2019-12-31 | -$3.94M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$12.83M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | -$8.89M 10-Q · filed 2020-12-10 | |||
| 2018-12-31 | -$7.91M 10-K · filed 2021-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |